APRE News and Press, Aprea Therapeutics Inc. From 04/03/24

2024-04-03 16:30:08 ET More on Aprea Therapeutics Aprea Therapeutics announces private placement financing of up to $34M Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea ...

2024-03-26 08:05:58 ET More on Aprea Therapeutics Aprea Therapeutics announces private placement financing of up to $34M Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea ...

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase ...

2024-03-18 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 08:49:04 ET More on Aprea Therapeutics Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea Therapeutics Read the full article on Seeking Alpha For further...

Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to...

Company plans to initiate Phase 1 ACESOT-1051 ( A Multi- C enter E valuation of WEE1 Inhibitor in Patients with Advanced So lid T umors, APR- 1051 ) clinical trial evaluating , highly selective, oral WEE1 inhibitor, f...

2024-03-08 02:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations...

2024-02-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...